Search Results for "Thyroid Cancer And Bevacizumab"
Original Source: Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Anaplastic Thyroid Cancer is a very aggressive disease. The investigators believe that angiogenesis is very important for these tumors to progress. Preclinical data is suggesting this. This is why we we prospectively want to treat these patients with avastin (and doxorubicin). However, local control is of major concern. Therefore, patients are initially treated with hyperfractionated radiotherapy and undergo surgery. Then they can enter this study.
Matching Channels
Matching News
[Comment] Treating advanced radioresistant differentiated thyroid cancer
Despite a decline in overall mortality from cancer in the USA, thyroid cancer incidence has more than doubled in the past decade, with an associated rise in mortality. Equivalent or even more pronounc...
Thyroid Journal Publishes First Comprehensive Guidelines For Managing Anaplastic Thyroid Cancer
Anaplastic thyroid cancer is a rare form of thyroid tumor, but it is also the most deadly. Newly developed evidence-based recommendations for the diagnosis, treatment, and long-term monitoring and fol...
First comprehensive guidelines for managing anaplastic thyroid cancer published in Thyroid journal
(Mary Ann Liebert, Inc./Genetic Engineering News) Naplastic thyroid cancer is a rare form of thyroid tumor, but it is also the most deadly. Newly developed evidence-based recommendations for the diagn...
Bevacizumab Slows Progression Of Metastatic Breast Cancer But Has No Impact On Survival
The cancer drug bevacizumab (Avastin®) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researc...
Metastatic breast cancer: Bevacizumab slows progression, but has no impact on survival
The cancer drug bevacizumab (Avastin) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researche...
Thyroid cancer is the ninth most common cancer in the United States, with an incidence that has been increasing sharply since the mid-1990s. The majority of thyroid cancers are papillary thyroid cance...
Thyroid journal publishes new ATA guidelines for management of anaplastic thyroid cancer
Anaplastic thyroid cancer is a rare form of thyroid tumor, but it is also the most deadly. Newly developed evidence-based recommendations for the diagnosis, treatment, and long-term monitoring and fol...
Breast cancer dug bevacizumab slows progression but has no overall survival benefit
The cancer drug bevacizumab (Avastin®) offers only a modest benefit in prolonging disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane resea...
Matching PubMed Articles
Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes.
BACKGROUND: Bevacizumab is a humanized monoclonal antibody that blocks vascular endothelial factor. It demonstrated an efficacy in many cancer types. The standard recommendation of administration is t...
PURPOSE: To evaluate the pharmacokinetics of bevacizumab following IP and IV administration, and to investigate combined bevacizumab therapy (IP or IV) with IP paclitaxel or carboplatin in a mouse mod...
Using bevacizumab to treat metastatic cancer: UK consensus guidelines.
Concise guidance is lacking for the use of bevacizumab by practicing oncologists. Eight oncologists with experience of bevacizumab were joined by a cardiologist interested in treating hypertension to...
Perirenal hematoma associated with bevacizumab treatment.
We now describe the first example of a patient who developed perirenal hematoma during the course of bevacizumab-containing chemotherapy. A 59-years-old woman with metastatic rectal cancer treated wit...
Bevacizumab: current updates in treatment.
PURPOSE OF REVIEW: Drugs targeting angiogenesis are rapidly being incorporated into cancer treatment regimens. Bevacizumab was the first antiangiogenesis agent to gain approval by the Food and Drug Ad...
